Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury

Yao,Junchao; Zheng,Kebin; Zhang,Xiang

doi:10.3892/mmr.2015.4292

Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury

Authors:
- Junchao Yao
- Kebin Zheng
- Xiang Zhang
View Affiliations

Affiliations: Department of Neurosurgery, Central Hospital of Cangzhou, Cangzhou, Hebei 061000, P.R. China, Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China
Published online on: September 7, 2015 https://doi.org/10.3892/mmr.2015.4292
Pages: 6591-6597
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traumatic brain injury (TBI) is one of the leading causes of mortality and morbidity in adults and children worldwide. Recent studies have demonstrated that both apoptosis and autophagy participate in TBI‑induced neuronal cell death and functional loss. The peroxisome proliferator‑activated receptor‑γ (PPAR‑γ) agonist rosiglitazone (RSG) is a well‑known anti‑inflammatory, which carries out its effects via the activation of PPAR‑γ. Previous studies have suggested that RSG may exert neuroprotective effects in animal models of both chronic and acute brain injury; however, whether RSG is involved in autophagic neuronal death following TBI remains to be elucidated. The present study aimed to determine whether RSG carries out its neuroprotective properties via the attenuation of neuronal apoptosis and autophagy, following TBI in a rat model. Furthermore, the role of RSG was investigated with regards to the modulation of inflammation and glutamate excitotoxicity, and the impact of RSG on functional recovery following TBI was determined. The rats were subjected to controlled cortical impact injury, prior to being randomly divided into three groups: A sham‑operated group, a TBI group, and an RSG treatment group. The RSG treatment group was intraperitoneally treated with 2 mg/kg RSG immediately after TBI. The results of the present study demonstrated that RSG treatment following TBI significantly reduced neuronal apoptosis and autophagy, and increased functional recovery. These effects were correlated with a decrease in the protein expression levels of tumor necrosis factor α and interleukin‑6. However, no significant changes were observed in the protein expression levels of glutamate transporter‑1 in the brain cortex. The results of the present study provide in vivo evidence that RSG may exert neuroprotective effects via the inhibition of neuronal apoptosis and autophagy following experimental TBI in rats, and the mechanism underlying these effects may be associated with the anti‑inflammatory action of RSG. The present study offers a novel insight into the potential use of RSG as a neuroprotective agent for the treatment of cerebral injuries.

View Figures

View References

1	Liu Y, Yi XC, Guo G, Long QF, Wang XA, Zhong J, Liu WP, Fei Z, Wang DM and Liu J: Basic fibroblast growth factor increases the transplantation-mediated therapeutic effect of bone mesenchymal stem cells following traumatic brain injury. Mol Med Rep. 9:333–339. 2014.
2	Greve MW and Zink BJ: Pathophysiology of traumatic brain injury. Mt Sinai J Med. 76:97–104. 2009. View Article : Google Scholar : PubMed/NCBI
3	Gaetz M: The neurophysiology of brain injury. Clin Neurophysiol. 115:4–18. 2004. View Article : Google Scholar : PubMed/NCBI
4	Headrick JP, Bendall MR, Faden AI and Vink R: Dissociation of adenosine levels from bioenergetic state in experimental brain trauma: Potential role in secondary injury. J Cereb Blood Flow Metab. 14:853–861. 1994. View Article : Google Scholar : PubMed/NCBI
5	Khan M, Im YB, Shunmugavel A, Gilg AG, Dhindsa RK, Singh AK and Singh I: Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. J Neuroinflammation. 6:322009. View Article : Google Scholar : PubMed/NCBI
6	Cui C, Cui Y, Gao J, Sun L, Wang Y, Wang K, Li R, Tian Y, Song S and Cui J: Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. Neurol Sci. 35:695–700. 2014. View Article : Google Scholar
7	Wang YQ, Wang L, Zhang MY, Wang T, Bao HJ, Liu WL, Dai DK, Zhang L, Chang P, Dong WW, et al: Necrostatin-1 suppresses autophagy and apoptosis in mice traumatic brain injury model. Neurochem Res. 37:1849–1858. 2012. View Article : Google Scholar : PubMed/NCBI
8	Rink A, Fung KM, Trojanowski JQ, Lee VM, Neugebauer E and McIntosh TK: Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Am J Pathol. 147:1575–1583. 1995.PubMed/NCBI
9	Clark RS, Kochanek PM, Watkins SC, Chen M, Dixon CE, Seidberg NA, Melick J, Loeffert JE, Nathaniel PD, Jin KL and Graham SH: Caspase-3 mediated neuronal death after traumatic brain injury in rats. J Neurochem. 74:740–753. 2000. View Article : Google Scholar : PubMed/NCBI
10	Graham SH, Chen J and Clark RS: Bcl-2 family gene products in cerebral ischemia and traumatic brain injury. J Neurotrauma. 17:831–841. 2000. View Article : Google Scholar : PubMed/NCBI
11	Clark RS, Bayir H, Chu CT, Alber SM, Kochanek PM and Watkins SC: Autophagy is increased in mice after traumatic brain injury and is detectable in human brain after trauma and critical illness. Autophagy. 4:88–90. 2008. View Article : Google Scholar
12	Cao Y and Klionsky DJ: Physiological functions of Atg6/Beclin 1: A unique autophagy-related protein. Cell Res. 17:839–849. 2007. View Article : Google Scholar : PubMed/NCBI
13	Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al-Haddad W, Dhindsa S and Dandona P: Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 89:2728–2735. 2004. View Article : Google Scholar : PubMed/NCBI
14	Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA and Roses AD; Rosiglitazone in Alzheimer's Disease Study Group: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6:246–254. 2006.PubMed/NCBI
15	Schütz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schürmann B, Zimmer A and Heneka MT: The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 25:7805–7812. 2005. View Article : Google Scholar : PubMed/NCBI
16	Chaturvedi RK and Beal MF: PPAR: A therapeutic target in Parkinson's disease. J Neurochem. 106:506–518. 2008. View Article : Google Scholar : PubMed/NCBI
17	Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH and Chen J: Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem. 97:435–448. 2006. View Article : Google Scholar : PubMed/NCBI
18	Zhang Q, Hu W, Meng B and Tang T: PPARγ agonist rosiglitazone is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats. Neurol Res. 32:852–859. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yi JH, Park SW, Brooks N, Lang BT and Vemuganti R: PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244:164–172. 2008. View Article : Google Scholar : PubMed/NCBI
20	Stoica BA and Faden AI: Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics. 7:3–12. 2010. View Article : Google Scholar : PubMed/NCBI
21	Xu M and Zhang HL: Death and survival of neuronal and astrocytic cells in ischemic brain injury: A role of autophagy. Acta Pharmacol Sin. 32:1089–1099. 2011. View Article : Google Scholar : PubMed/NCBI
22	Erlich S, Alexandrovich A, Shohami E and Pinkas-Kramarski R: Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis. 26:86–93. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lai Y, Hickey RW, Chen Y, Bayir H, Sullivan ML, Chu CT, Kochanek PM, Dixon CE, Jenkins LW, Graham SH, et al: Autophagy is increased after traumatic brain injury in mice and is partially inhibited by the antioxidant gamma-glutamylcysteinyl ethyl ester. J Cereb Blood Flow Metab. 28:540–550. 2008. View Article : Google Scholar
24	Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O and Kossmann T: IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-alpha, TGF-beta 1 and blood-brain barrier function. J Neuroimmunol. 101:211–221. 1999. View Article : Google Scholar : PubMed/NCBI
25	He J, Evans CO, Hoffman SW, Oyesiku NM and Stein DG: Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol. 189:404–412. 2004. View Article : Google Scholar : PubMed/NCBI
26	Palmer AM, Marion DW, Botscheller ML, Swedlow PE, Styren SD and DeKosky ST: Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J Neurochem. 61:2015–2024. 1993. View Article : Google Scholar : PubMed/NCBI
27	Yi JH and Hazell AS: Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int. 48:394–403. 2006. View Article : Google Scholar : PubMed/NCBI
28	Rao VL, Başkaya MK, Doğan A, Rothstein JD and Dempsey RJ: Traumatic brain injury down-regulates glial glutamate transporter (GLT-1 and GLAST) proteins in rat brain. J Neurochem. 70:2020–2027. 1998.PubMed/NCBI